Luise Fischer,Nora Grieb,Patrick Born,Ronald Weiss,Sabine Seiffert,Andreas Boldt,Stephan Fricke,Paul Franz,Simone Heyn,Anne Sophie Kubasch,Ronny Baber,Heike Weidner,Song Yau Wang,Enrica Bach,Sandra Hoffmann,Jule Ussmann,Janine Kirchberg,Saskia Hell,Sebastian Schwind,Klaus H. Metzeler,Marco Herling,Madlen Jentzsch,Georg-Nikolaus Franke,Ulrich Sack,Kristin Reiche,Ulrike Köhl,Uwe Platzbecker,Vladan Vucinic,Maximilian Merz

Abstract:B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited. Therefore, we performed a comprehensive flow cytometry analysis of 27 RRMM patients treated with Idecabtagene vicleucel (Ide-cel) to assess the expansion capacity, persistence and effects on bystander cells of BCMA-targeting CAR T cells. Additionally, we addressed side effects, like cytokine release syndrome (CRS) and cytopenia. Our results show that in vivo expansion of CD8 + CAR T cells is correlated to response, however persistence is not essential for durable remission in RRMM patients. In addition, our data provide evidence, that an increased fraction of CD8 + T cells at day of leukapheresis in combination with successful lymphodepletion positively influence the outcome. We show that patients at risk for higher-grade CRS can be identified already prior to lymphodepletion. Our extensive characterization contributes to a better understanding of the dynamics and effects of BCMA-targeting CAR T cells, in order to predict the response of individual patients as well as side effects, which can be counteracted at an early stage or even prevented.

What problem does this paper attempt to address?

This paper aims to address the lack of data in the research on cell kinetics and its relationship with treatment response, drug resistance, and the occurrence of cytokine - release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) after receiving BCMA - targeted chimeric antigen receptor T - cell (CAR - T - cell) treatment. Specifically, through comprehensive flow cytometry analysis, the paper explored the CAR - T - cell expansion ability, durability, and the impact on bystander cells in 27 RRMM patients after receiving idecabtagene vicleucel (Ide - cel) treatment, and evaluated related side effects such as CRS and cytopenia. The research results show that the in - vivo expansion of CD8+ CAR - T - cells is related to the treatment response, but durability is not necessary for continuous remission. In addition, the study also found that a higher proportion of CD8+ T - cells on the day of leukapheresis, combined with successful lymphodepletion, can positively influence the treatment outcome. The study also revealed that patients at a higher risk of CRS can be identified before lymphodepletion. These detailed characteristics contribute to a better understanding of the kinetics and effects of BCMA - targeted CAR - T - cells, in order to predict the response and side effects of individual patients, and even prevent the occurrence of side effects at an early stage.

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma